Genelux (NASDAQ:GNLX) CEO Sells $92,016.21 in Stock

Genelux Corporation (NASDAQ:GNLX) CEO Thomas Zindrick sold 34,463 shares of Genelux stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $2.67, for a total value of $92,016.21. Following the transaction, the chief executive officer directly owned 1,226,427 shares of the company’s stock, valued at $3,274,560.09. The trade was a 2.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Thomas Zindrick also recently made the following trade(s):

• On Tuesday, August 4th, Thomas Zindrick sold 3,023 shares of Genelux stock. The stock was sold at an average price of $2.95, for a total transaction of $8,917.85.

Genelux Trading Down 3.2%

Shares of NASDAQ:GNLX opened at $2.44 on Friday. Genelux Corporation has a 12 month low of $2.29 and a 12 month high of $8.53. The stock has a market cap of $110.39 million, a P/E ratio of -2.84 and a beta of 0.57. The company has a 50 day moving average of $2.81 and a 200 day moving average of $2.78.

Genelux (NASDAQ:GNLX) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). On average, equities analysts forecast that Genelux Corporation will post -0.81 earnings per share for the current fiscal year.

Institutional Trading of Genelux

Several large investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. purchased a new position in Genelux during the 1st quarter valued at $239,000. Jane Street Group LLC purchased a new stake in shares of Genelux in the 1st quarter worth about $190,000. Geode Capital Management LLC boosted its stake in shares of Genelux by 1.8% during the 2nd quarter. Geode Capital Management LLC now owns 318,825 shares of the company’s stock valued at $915,000 after purchasing an additional 5,596 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Genelux during the 2nd quarter valued at about $92,000. Finally, Raymond James Financial Inc. increased its position in shares of Genelux by 22.6% during the second quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock valued at $83,000 after buying an additional 5,333 shares during the period. Institutional investors own 37.33% of the company’s stock.

Analyst Upgrades and Downgrades

GNLX has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a report on Friday, July 17th. Wall Street Zen upgraded shares of Genelux from a “strong sell” rating to a “sell” rating in a research report on Sunday, August 23rd. Finally, Benchmark reaffirmed a “speculative buy” rating on shares of Genelux in a research note on Tuesday, August 18th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $18.00.

About Genelux

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.